- Previous Close
46.20 - Open
47.82 - Bid 44.99 x 100
- Ask 45.49 x 100
- Day's Range
43.45 - 47.82 - 52 Week Range
11.39 - 51.80 - Volume
1,994,579 - Avg. Volume
1,095,380 - Market Cap (intraday)
3.699B - Beta (5Y Monthly) 0.42
- PE Ratio (TTM)
-- - EPS (TTM)
-2.00 - Earnings Date Jan 7, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
63.50
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom.
www.veronapharma.comRecent News: VRNA
View MorePerformance Overview: VRNA
Trailing total returns as of 1/11/2025, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: VRNA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: VRNA
View MoreValuation Measures
Market Cap
3.70B
Enterprise Value
3.49B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
650.02
Price/Book (mrq)
28.35
Enterprise Value/Revenue
619.67
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-28.05%
Return on Equity (ttm)
-78.03%
Revenue (ttm)
5.62M
Net Income Avi to Common (ttm)
-153.72M
Diluted EPS (ttm)
-2.00
Balance Sheet and Cash Flow
Total Cash (mrq)
336.04M
Total Debt/Equity (mrq)
93.73%
Levered Free Cash Flow (ttm)
-60.08M